MARC details
| 000 -LEADER |
|---|
| fixed length control field |
03388nam a22006137a 4500 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
190827s20192019 xxu||||| |||| 00| 0 eng d |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER |
|---|
| International Standard Serial Number |
1523-3790 |
| 024 ## - OTHER STANDARD IDENTIFIER |
|---|
| Standard number or code |
10.1007/s11912-019-0835-x [doi] |
| 024 ## - OTHER STANDARD IDENTIFIER |
|---|
| Standard number or code |
10.1007/s11912-019-0835-x [pii] |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloging agency |
Ovid MEDLINE(R) |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) |
|---|
| PMID |
31410582 |
| 245 ## - TITLE STATEMENT |
|---|
| Title |
Role of Anti-EGFR Targeted Therapies in Stage III Locally Advanced Non-small Cell Lung Cancer: Give or Not to Give?. [Review] |
| 251 ## - Source |
|---|
| Source |
Current Oncology Reports. 21(9):84, 2019 08 13. |
| 252 ## - Abbreviated Source |
|---|
| Abbreviated source |
Curr Oncol Rep. 21(9):84, 2019 08 13. |
| 252 ## - Abbreviated Source |
|---|
| Former abbreviated source |
Curr Oncol Rep. 21(9):84, 2019 Aug 13. |
| 253 ## - Journal Name |
|---|
| Journal name |
Current oncology reports |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. |
|---|
| Year |
2019 |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. |
|---|
| Manufacturer |
FY2020 |
| 265 ## - SOURCE FOR ACQUISITION/SUBSCRIPTION ADDRESS [OBSOLETE] |
|---|
| Publication status |
epublish |
| 266 ## - Date added to catalog |
|---|
| Date added to catalog |
2019-08-27 |
| 268 ## - Previous citation |
|---|
| -- |
Current Oncology Reports. 21(9):84, 2019 Aug 13. |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
PURPOSE OF REVIEW: Identification of targetable mutations such as EGFR has allowed opportunity for Tyrosine Kinase Inhibitor (TKI) therapy for lung cancer treatment. EGFR-TKIs have revolutionized treatment of advanced EGFR mutant Non-Small Cell Lung Cancer (NSCLC), but there is little evidence that EGFR-TKI treatment is effective in stage III NSCLC. Here we discuss recent evidence supporting the use of EGFR-TKI therapy in combination with chemotherapy and radiation in stage III NSCLC. |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
RECENT FINDINGS: Recent results of small trials testing EGFR-TKI therapy in combination with chemoradiation showed promising efficacy, improved outcomes, and a tolerable toxicity profile when administered to patients with EGFR mutant stage III NSCLC. However, strong supporting evidence regarding EGFR-TKI therapy in stage III NSCLC is lacking because previous trials involved a small patient population or were terminated due to slow participant accrual. Despite the lack of large randomized clinical trials, results from early-stage trials highlight promising future directions for investigating the use of EGFR-TKI therapy in stage III NSCLC treatment. |
| 546 ## - LANGUAGE NOTE |
|---|
| Language note |
English |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
*Carcinoma, Non-Small-Cell Lung/dt [Drug Therapy] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
*Lung Neoplasms/dt [Drug Therapy] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
*Protein Kinase Inhibitors/tu [Therapeutic Use] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Antineoplastic Agents/pd [Pharmacology] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Antineoplastic Agents/tu [Therapeutic Use] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Carcinoma, Non-Small-Cell Lung/en [Enzymology] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Carcinoma, Non-Small-Cell Lung/ge [Genetics] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Carcinoma, Non-Small-Cell Lung/pa [Pathology] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Clinical Trials as Topic |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
ErbB Receptors/ai [Antagonists & Inhibitors] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
ErbB Receptors/ge [Genetics] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Humans |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Lung Neoplasms/en [Enzymology] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Lung Neoplasms/ge [Genetics] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Lung Neoplasms/pa [Pathology] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Molecular Targeted Therapy/mt [Methods] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Mutation |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Neoplasm Staging |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Protein Kinase Inhibitors/pd [Pharmacology] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Randomized Controlled Trials as Topic |
| 651 ## - SUBJECT ADDED ENTRY--GEOGRAPHIC NAME |
|---|
| Institution |
Washington Cancer Institute |
| 657 ## - INDEX TERM--FUNCTION |
|---|
| Medline publication type |
Journal Article |
| 657 ## - INDEX TERM--FUNCTION |
|---|
| Medline publication type |
Review |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Local Authors |
Desai, Sanjal |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Local Authors |
Kim, Chul |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Local Authors |
Veytsman, Irina |
| 790 ## - Authors |
|---|
| All authors |
Desai S, Kim C, Veytsman I |
| 856 ## - ELECTRONIC LOCATION AND ACCESS |
|---|
| DOI |
<a href="https://dx.doi.org/10.1007/s11912-019-0835-x">https://dx.doi.org/10.1007/s11912-019-0835-x</a> |
| Public note |
https://dx.doi.org/10.1007/s11912-019-0835-x |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Koha item type |
Journal Article |
| Item type description |
Article |
